Literature DB >> 3489467

Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease.

H M Belmont, P Hopkins, H S Edelson, H B Kaplan, R Ludewig, G Weissmann, S Abramson.   

Abstract

To determine whether activated complement components appear in the circulation of patients with systemic lupus erythematosus (SLE), we measured C5a and C3a by radioimmunoassay. Mean C5a concentration in the plasma of acutely ill SLE patients was 46.0 ng/ml, compared with 17.1 ng/ml in normal controls (P less than 0.01). Mean C3a concentration in patients with severe disease was 526 ng/ml, compared with 134 ng/ml in controls (P less than 0.01). In patients with moderately active SLE, the mean C3a concentration, but not the mean C5a concentration, was also elevated. In addition, C3a was elevated in 15 or 21 patients with active SLE, whereas low levels of C3 or C4 were noted in only 7 of these 21 patients. We conclude that the measurement of complement-derived anaphylatoxins may be useful in the management of patients with SLE. In addition, we suggest that these circulating mediators may contribute to the pathogenesis of vascular injury in patients with the disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489467     DOI: 10.1002/art.1780290905

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  23 in total

Review 1.  C1q receptors.

Authors:  P Eggleton; A J Tenner; K B Reid
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

Review 2.  Pleuropulmonary manifestations of systemic lupus erythematosus.

Authors:  M P Keane; J P Lynch
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

Review 3.  Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future.

Authors:  Chau-Ching Liu; Joseph M Ahearn; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 4.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

5.  Inhibition of C5a receptor alleviates experimental CNS lupus.

Authors:  Alexander Jacob; Bradley Hack; Tao Bai; James R Brorson; Richard J Quigg; Jessy J Alexander
Journal:  J Neuroimmunol       Date:  2010-03-05       Impact factor: 3.478

6.  Complement activation is involved in biological responses to leukocyte adsorptive apheresis.

Authors:  Shoichi Nishise; Yuji Takeda; Hiroaki Takeda; Katsuyoshi Ishihama; Tadahisa Fukui; Sumio Kawata
Journal:  Dig Dis Sci       Date:  2006-04-27       Impact factor: 3.199

Review 7.  The role of neutrophils in vascular injury: a summary of signal transduction mechanisms in cell/cell interactions.

Authors:  G Weissmann
Journal:  Springer Semin Immunopathol       Date:  1989

8.  C3aR inhibition reduces neurodegeneration in experimental lupus.

Authors:  A Jacob; L Bao; J Brorson; R J Quigg; J J Alexander
Journal:  Lupus       Date:  2009-11-09       Impact factor: 2.911

Review 9.  The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.

Authors:  Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

Review 10.  New advances in measurement of complement activation: lessons of systemic lupus erythematosus.

Authors:  Chau-Ching Liu; Susan Manzi; Natalya Danchenko; Joseph M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.